Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy.

Ishiki A, Harada R, Kai H, Sato N, Totsune T, Tomita N, Watanuki S, Hiraoka K, Ishikawa Y, Funaki Y, Iwata R, Furumoto S, Tashiro M, Sasano H, Kitamoto T, Kudo Y, Yanai K, Furukawa K, Okamura N, Arai H.

Acta Neuropathol Commun. 2018 Jun 29;6(1):53. doi: 10.1186/s40478-018-0556-7.

2.

Case of progressive supranuclear palsy detected by tau imaging with [18 F]THK-5351 before the appearance of characteristic clinical features.

Shimizu S, Imabayashi E, Takenoshita N, Okamura N, Furumoto S, Kudo Y, Matsuda H, Hanyu H.

Geriatr Gerontol Int. 2018 Mar;18(3):501-502. doi: 10.1111/ggi.13229. No abstract available.

PMID:
29542297
3.

Practical microscale one-pot radiosynthesis of 18 F-labeled probes.

Iwata R, Pascali C, Terasaki K, Ishikawa Y, Furumoto S, Yanai K.

J Labelled Comp Radiopharm. 2018 Jun 15;61(7):540-549. doi: 10.1002/jlcr.3618. Epub 2018 Apr 17.

PMID:
29520821
4.

Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau.

Betthauser TJ, Ellison PA, Murali D, Lao PJ, Barnhart TE, Furumoto S, Okamura N, Johnson SC, Engle JW, Nickles RJ, Christian BT.

Appl Radiat Isot. 2017 Dec;130:230-237. doi: 10.1016/j.apradiso.2017.10.002. Epub 2017 Oct 4.

PMID:
29031087
5.

[18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia.

Lee H, Seo S, Lee SY, Jeong HJ, Woo SH, Lee KM, Lee YB, Park KH, Heo JH, Yoon CW, Kang JM, Cho J, Okamura N, Furumoto S, Yanai K, Na DL, Ido T, Villemagne VL, Noh Y.

Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):62-69. doi: 10.1097/WAD.0000000000000216.

PMID:
29028649
6.

Development of molecular imaging probe targeted at Alzheimer's disease pathology.

Okamura N, Harada R, Furumoto S, Nakamura T, Yanai K, Kudo Y.

Nihon Yakurigaku Zasshi. 2017;150(4):172-176. doi: 10.1254/fpj.150.172. Japanese. No abstract available.

PMID:
28966214
7.

Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease.

Kang JM, Lee SY, Seo S, Jeong HJ, Woo SH, Lee H, Lee YB, Yeon BK, Shin DH, Park KH, Kang H, Okamura N, Furumoto S, Yanai K, Villemagne VL, Seong JK, Na DL, Ido T, Cho J, Lee KM, Noh Y.

Neurobiol Aging. 2017 Nov;59:210-219. doi: 10.1016/j.neurobiolaging.2017.08.008. Epub 2017 Aug 12.

PMID:
28890300
8.

Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease.

Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, Tago T, Tomita N, Watanuki S, Hiraoka K, Ishikawa Y, Funaki Y, Nakamura T, Yoshikawa T, Iwata R, Tashiro M, Sasano H, Kitamoto T, Yanai K, Arai H, Kudo Y, Okamura N.

J Nucl Med. 2018 Apr;59(4):671-674. doi: 10.2967/jnumed.117.197426. Epub 2017 Sep 1.

PMID:
28864633
9.

Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer's disease: A combined positron emission tomography/magnetic resonance imaging study.

Sone D, Imabayashi E, Maikusa N, Okamura N, Furumoto S, Kudo Y, Ogawa M, Takano H, Yokoi Y, Sakata M, Tsukamoto T, Kato K, Matsuda H.

Alzheimers Dement (Amst). 2017 Aug 4;9:35-40. doi: 10.1016/j.dadm.2017.07.001. eCollection 2017.

10.

A comparison of five partial volume correction methods for Tau and Amyloid PET imaging with [18F]THK5351 and [11C]PIB.

Shidahara M, Thomas BA, Okamura N, Ibaraki M, Matsubara K, Oyama S, Ishikawa Y, Watanuki S, Iwata R, Furumoto S, Tashiro M, Yanai K, Gonda K, Watabe H.

Ann Nucl Med. 2017 Aug;31(7):563-569. doi: 10.1007/s12149-017-1185-0. Epub 2017 Jun 21.

PMID:
28639126
11.

Minimization of the amount of Kryptofix 222 - KHCO3 for applications to microscale 18F-radiolabeling.

Iwata R, Pascali C, Terasaki K, Ishikawa Y, Furumoto S, Yanai K.

Appl Radiat Isot. 2017 Jul;125:113-118. doi: 10.1016/j.apradiso.2017.04.021. Epub 2017 Apr 13.

PMID:
28431335
12.

Prediction of the Clinical SUV Ratio in Amyloid PET Imaging Using a Biomathematic Modeling Approach Toward the Efficient Development of a Radioligand.

Arakawa Y, Nai Y, Shidahara M, Furumoto S, Seki C, Okamura N, Tashiro M, Kudo Y, Yanai K, Gonda K, Watabe H.

J Nucl Med. 2017 Aug;58(8):1285-1292. doi: 10.2967/jnumed.116.183566. Epub 2017 Jan 6.

PMID:
28062596
13.

Development of [11C]/[3H]THK-5351 - A potential novel carbon-11 tau imaging PET radioligand.

Stepanov V, Svedberg M, Jia Z, Krasikova R, Lemoine L, Okamura N, Furumoto S, Mitsios N, Mulder J, Långström B, Nordberg A, Halldin C.

Nucl Med Biol. 2017 Mar;46:50-53. doi: 10.1016/j.nucmedbio.2016.12.004. Epub 2016 Dec 9.

PMID:
28013122
14.

A report of the automated radiosynthesis of the tau positron emission tomography radiopharmaceutical, [18 F]-THK-5351.

Neelamegam R, Yokell DL, Rice PA, Furumoto S, Kudo Y, Okamura N, El Fakhri G.

J Labelled Comp Radiopharm. 2017 Feb;60(2):140-146. doi: 10.1002/jlcr.3482. Epub 2017 Jan 25.

PMID:
27859483
15.

In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317.

Betthauser TJ, Lao PJ, Murali D, Barnhart TE, Furumoto S, Okamura N, Stone CK, Johnson SC, Christian BT.

J Nucl Med. 2017 Jun;58(6):996-1002. doi: 10.2967/jnumed.116.182980. Epub 2016 Nov 10.

16.

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

Ishiki A, Harada R, Okamura N, Tomita N, Rowe CC, Villemagne VL, Yanai K, Kudo Y, Arai H, Furumoto S, Tashiro M, Furukawa K.

Eur J Neurol. 2017 Jan;24(1):130-136. doi: 10.1111/ene.13164. Epub 2016 Oct 31.

PMID:
27797445
17.

In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.

Kikuchi A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Oshima R, Yoshida S, Kobayashi J, Ezura M, Kobayashi M, Tano O, Mugikura S, Iwata R, Ishiki A, Furukawa K, Arai H, Furumoto S, Tashiro M, Yanai K, Kudo Y, Takeda A, Aoki M.

Neurology. 2016 Nov 29;87(22):2309-2316. Epub 2016 Oct 28.

18.

Erratum to: Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351.

Harada R, Furumoto S, Tago T, Furukawa K, Ishiki A, Tomita N, Iwata R, Tashiro M, Arai H, Yanai K, Kudo Y, Okamura N.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):177. No abstract available.

PMID:
27734120
19.

Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351.

Harada R, Furumoto S, Tago T, Furukawa K, Ishiki A, Tomita N, Iwata R, Tashiro M, Arai H, Yanai K, Kudo Y, Okamura N.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2211-2218. Epub 2016 Jul 19. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):177. Katsutoshi, F [corrected to Furukawa, K].

PMID:
27430946
20.

Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life.

Asano R, Koyama N, Hagiwara Y, Masakari Y, Orimo R, Arai K, Ogata H, Furumoto S, Umetsu M, Kumagai I.

FEBS Open Bio. 2016 May 16;6(6):594-602. doi: 10.1002/2211-5463.12073. eCollection 2016 Jun.

21.

Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.

Lockhart SN, Baker SL, Okamura N, Furukawa K, Ishiki A, Furumoto S, Tashiro M, Yanai K, Arai H, Kudo Y, Harada R, Tomita N, Hiraoka K, Watanuki S, Jagust WJ.

PLoS One. 2016 Jun 29;11(6):e0158460. doi: 10.1371/journal.pone.0158460. eCollection 2016.

22.

18F-Labeled 2-Arylquinoline Derivatives for Tau Imaging: Chemical, Radiochemical, Biological and Clinical Features.

Furumoto S, Tago T, Harada R, Kudo Y, Okamura N.

Curr Alzheimer Res. 2017;14(2):178-185. Review.

PMID:
27334944
23.

[Tau imaging].

Kudo Y, Furumoto S, Harada R, Okamura N.

Nihon Rinsho. 2016 Mar;74(3):404-9. Japanese.

PMID:
27025077
24.

Radiosynthesis and preliminary biological evaluation of a new (18)F-labeled triethylene glycol derivative of triphenylphosphonium.

Tominaga T, Ito H, Ishikawa Y, Iwata R, Ishiwata K, Furumoto S.

J Labelled Comp Radiopharm. 2016 Mar;59(3):117-23. doi: 10.1002/jlcr.3379. Epub 2016 Feb 10.

PMID:
26861736
25.

Advances in the development of tau PET radiotracers and their clinical applications.

Okamura N, Harada R, Furukawa K, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y.

Ageing Res Rev. 2016 Sep;30:107-13. doi: 10.1016/j.arr.2015.12.010. Epub 2016 Jan 21. Review.

PMID:
26802556
26.

Characteristics of Tau and Its Ligands in PET Imaging.

Harada R, Okamura N, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y.

Biomolecules. 2016 Jan 6;6(1):7. doi: 10.3390/biom6010007. Review.

27.

Synthesis and Characterization of ¹⁸F-Interleukin-8 Using a Cell-Free Translation System and 4-¹⁸F-Fluoro-L-Proline.

Harada R, Furumoto S, Yoshikawa T, Ishikawa Y, Shibuya K, Okamura N, Ishiwata K, Iwata R, Yanai K.

J Nucl Med. 2016 Apr;57(4):634-9. doi: 10.2967/jnumed.115.162602. Epub 2016 Jan 7.

28.

Performance evaluation of the small-animal PET scanner ClairvivoPET using NEMA NU 4-2008 Standards.

Sato K, Shidahara M, Watabe H, Watanuki S, Ishikawa Y, Arakawa Y, Nai YH, Furumoto S, Tashiro M, Shoji T, Yanai K, Gonda K.

Phys Med Biol. 2016 Jan 21;61(2):696-711. doi: 10.1088/0031-9155/61/2/696. Epub 2015 Dec 30.

PMID:
26716872
29.

Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease.

Tago T, Furumoto S, Okamura N, Harada R, Adachi H, Ishikawa Y, Yanai K, Iwata R, Kudo Y.

J Nucl Med. 2016 Apr;57(4):608-14. doi: 10.2967/jnumed.115.166652. Epub 2015 Dec 23.

30.

18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.

Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Tago T, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y.

J Nucl Med. 2016 Feb;57(2):208-14. doi: 10.2967/jnumed.115.164848. Epub 2015 Nov 5.

31.

Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography.

Ishiki A, Okamura N, Furukawa K, Furumoto S, Harada R, Tomita N, Hiraoka K, Watanuki S, Ishikawa Y, Tago T, Funaki Y, Iwata R, Tashiro M, Yanai K, Kudo Y, Arai H.

PLoS One. 2015 Oct 13;10(10):e0140311. doi: 10.1371/journal.pone.0140311. eCollection 2015.

32.

Preclinical Evaluation of [(18)F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer.

Tago T, Furumoto S, Okamura N, Harada R, Adachi H, Ishikawa Y, Yanai K, Iwata R, Kudo Y.

Mol Imaging Biol. 2016 Apr;18(2):258-66. doi: 10.1007/s11307-015-0879-8.

PMID:
26194011
33.

Amyloid deposits and response to shunt surgery in idiopathic normal-pressure hydrocephalus.

Hiraoka K, Narita W, Kikuchi H, Baba T, Kanno S, Iizuka O, Tashiro M, Furumoto S, Okamura N, Furukawa K, Arai H, Iwata R, Mori E, Yanai K.

J Neurol Sci. 2015 Sep 15;356(1-2):124-8. doi: 10.1016/j.jns.2015.06.029. Epub 2015 Jun 16.

PMID:
26095458
34.

Quantitative kinetic analysis of PET amyloid imaging agents [(11)C]BF227 and [(18)F]FACT in human brain.

Shidahara M, Watabe H, Tashiro M, Okamura N, Furumoto S, Watanuki S, Furukawa K, Arakawa Y, Funaki Y, Iwata R, Gonda K, Kudo Y, Arai H, Ishiwata K, Yanai K.

Nucl Med Biol. 2015 Sep;42(9):734-44. doi: 10.1016/j.nucmedbio.2015.05.001. Epub 2015 May 9.

PMID:
26093494
35.

[(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease.

Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Tago T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y.

Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1052-61. doi: 10.1007/s00259-015-3035-4. Epub 2015 Mar 20.

PMID:
25792456
36.

Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease.

Li Y, Tsui W, Rusinek H, Butler T, Mosconi L, Pirraglia E, Mozley D, Vallabhajosula S, Harada R, Furumoto S, Furukawa K, Arai H, Kudo Y, Okamura N, de Leon MJ.

J Nucl Med. 2015 Feb;56(2):270-3. doi: 10.2967/jnumed.114.149229. Epub 2015 Jan 8.

37.

Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.

Asano R, Shimomura I, Konno S, Ito A, Masakari Y, Orimo R, Taki S, Arai K, Ogata H, Okada M, Furumoto S, Onitsuka M, Omasa T, Hayashi H, Katayose Y, Unno M, Kudo T, Umetsu M, Kumagai I.

MAbs. 2014;6(5):1243-54. doi: 10.4161/mabs.29445. Epub 2014 Oct 30.

38.

Voyage au bout de la nuit: Aβ and tau imaging in dementias.

Zwan MD, Okamura N, Fodero-Tavoletti MT, Furumoto S, Masters CL, Rowe CC, Villemagne VL.

Q J Nucl Med Mol Imaging. 2014 Dec;58(4):398-412. Epub 2014 Oct 31. Review.

39.

Tau PET imaging in Alzheimer's disease.

Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y.

Curr Neurol Neurosci Rep. 2014 Nov;14(11):500. doi: 10.1007/s11910-014-0500-6. Review.

PMID:
25239654
40.

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL.

Brain. 2014 Jun;137(Pt 6):1762-71. doi: 10.1093/brain/awu064. Epub 2014 Mar 27.

PMID:
24681664
41.

Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.

Fodero-Tavoletti MT, Furumoto S, Taylor L, McLean CA, Mulligan RS, Birchall I, Harada R, Masters CL, Yanai K, Kudo Y, Rowe CC, Okamura N, Villemagne VL.

Alzheimers Res Ther. 2014 Feb 26;6(1):11. doi: 10.1186/alzrt240. eCollection 2014.

42.

In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease.

Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):816-26. doi: 10.1007/s00259-013-2681-7. Epub 2014 Feb 11.

PMID:
24514874
43.

Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging.

Tago T, Furumoto S, Okamura N, Harada R, Ishikawa Y, Arai H, Yanai K, Iwata R, Kudo Y.

J Labelled Comp Radiopharm. 2014 Jan;57(1):18-24. doi: 10.1002/jlcr.3133. Epub 2013 Oct 16.

PMID:
24448742
44.

Analysis of early phase [11C]BF-227 PET, and its application for anatomical standardization of late-phase images for 3D-SSP analysis.

Kaneta T, Okamura N, Arai A, Takanami K, Furukawa K, Tashiro M, Furumoto S, Iwata R, Takahashi S, Arai H, Yanai K, Kudo Y.

Jpn J Radiol. 2014 Mar;32(3):138-44. doi: 10.1007/s11604-013-0276-7. Epub 2014 Jan 10.

PMID:
24408078
45.

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.

Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M.

Neuron. 2013 Sep 18;79(6):1094-108. doi: 10.1016/j.neuron.2013.07.037.

46.

Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers.

Asano R, Hagiwara Y, Koyama N, Masakari Y, Orimo R, Arai K, Ogata H, Furumoto S, Umetsu M, Kumagai I.

FEBS J. 2013 Oct;280(19):4816-26. doi: 10.1111/febs.12451. Epub 2013 Aug 20.

47.

Use of a benzimidazole derivative BF-188 in fluorescence multispectral imaging for selective visualization of tau protein fibrils in the Alzheimer's disease brain.

Harada R, Okamura N, Furumoto S, Yoshikawa T, Arai H, Yanai K, Kudo Y.

Mol Imaging Biol. 2014 Feb;16(1):19-27. doi: 10.1007/s11307-013-0667-2.

PMID:
23868612
48.

Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.

Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y.

J Nucl Med. 2013 Aug;54(8):1420-7. doi: 10.2967/jnumed.112.117341. Epub 2013 Jul 15.

49.

In vitro and in vivo characterization of 2-deoxy-2-18F-fluoro-D-mannose as a tumor-imaging agent for PET.

Furumoto S, Shinbo R, Iwata R, Ishikawa Y, Yanai K, Yoshioka T, Fukuda H.

J Nucl Med. 2013 Aug;54(8):1354-61. doi: 10.2967/jnumed.112.113571. Epub 2013 Jul 10.

50.

Evaluation of the biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe [18F]FACT in humans.

Shidahara M, Tashiro M, Okamura N, Furumoto S, Furukawa K, Watanuki S, Hiraoka K, Miyake M, Iwata R, Tamura H, Arai H, Kudo Y, Yanai K.

EJNMMI Res. 2013 Apr 24;3(1):32. doi: 10.1186/2191-219X-3-32.

Supplemental Content

Loading ...
Support Center